Reviewing Blueprint Medicines (BPMC) and Advaxis (ADXS)

Blueprint Medicines (NASDAQ: BPMC) and Advaxis (NASDAQ:ADXS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Insider & Institutional Ownership

92.0% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 44.1% of Advaxis shares are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by company insiders. Comparatively, 7.2% of Advaxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Blueprint Medicines and Advaxis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines 0 0 9 0 3.00
Advaxis 0 0 2 0 3.00

Blueprint Medicines currently has a consensus target price of $70.47, indicating a potential downside of 0.15%. Advaxis has a consensus target price of $21.00, indicating a potential upside of 590.79%. Given Advaxis’ higher possible upside, analysts clearly believe Advaxis is more favorable than Blueprint Medicines.

Valuation and Earnings

This table compares Blueprint Medicines and Advaxis’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Blueprint Medicines $27.77 million 99.62 -$72.49 million ($3.42) -20.63
Advaxis $3.99 million 31.29 -$73.55 million ($2.29) -1.33

Blueprint Medicines has higher revenue and earnings than Advaxis. Blueprint Medicines is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.


This table compares Blueprint Medicines and Advaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines -437.83% -43.11% -34.38%
Advaxis -655.66% -93.54% -64.49%


Blueprint Medicines beats Advaxis on 8 of the 11 factors compared between the two stocks.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Advaxis Company Profile

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with's FREE daily email newsletter.

Leave a Reply